Methods Of Treating Ocular Disease
- Detailed Technology Description
- None
- Supplementary Information
- Patent Number: US7332470B2
Application Number: US2004823819A
Inventor: Fleiszig, Suzanne | Evans, David J. | Sack, Robert
Priority Date: 15 Apr 2003
Priority Number: US7332470B2
Application Date: 14 Apr 2004
Publication Date: 19 Feb 2008
IPC Current: A61K003800 | A61K003174 | A61K003817 | C07K001400
US Class: 5140028 | 514002 | 42407802 | 42407804 | 42407805 | 42407807 | 5140032 | 5140155 | 5140208 | 514887 | 514954 | 530350 | 530396
Assignee Applicant: The Regents of the University of California | The Research Foundation of State University of New Yorkbany
Title: Methods and compositions for treating ocular disease
Usefulness: Methods and compositions for treating ocular disease
Summary: As an artificial tear composition for storing, cleaning, re-writing or disinfecting a contact lens; for treating or preventing ocular diseases e.g. dry eye, keratitis, caused by microbe such as bacterial, viral, fungal or protozoan pathogen, gram-negative bacterium such as Pseudomonas aeruginosa in a contact-lens wearer (claimed).
Novelty: Treating ocular disease such as dry eye, keratitis and conjunctivitis comprises administering a surfactant protein (especially collectin) to the eye
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application No.
- 7332470
- Others
-
Tech ID/UC Case
17252/2003-050-0
Related Cases
2003-050-0
- *Abstract
-
Corneal clarity and transparency are the unique qualities of the corneal tissue that is critical for visual function. The cornea serves as a mechanical barrier against infections and trauma, and is considered part of the bio-defense system of the eye. This invention provides methods of protecting eye from ocular disease that relate to a substance that may be responsible for the regulation of the defense mechanism against corneal infections.
Potential applications of this substance include:
Treatment of ocular diseases.
Inclusion in solutions for contact lens cleaning and re-wetting.
Inclusion in artificial tear composition.
Transplant corneal surgery.
- *IP Issue Date
- Feb 19, 2008
- *Principal Investigator
-
Name: David Evans
Department:
Name: Suzanne Fleiszig
Department:
Name: Robert Sack
Department:
- Country/Region
- USA
